News
DGAP-News: BB Biotech AG schliesst aktuelles Aktienrückkaufprogramm ab und lanciert ein neues Aktienrückkaufprogramm
DGAP-News: BB Biotech AG schliesst aktuelles Aktienrückkaufprogramm ab und lanciert ein neues Aktienrückkaufprogramm
Evolva's AGM postponed to May 5, 2022 / agenda remains unchanged
Evolva's AGM postponed to May 5, 2022 / agenda remains unchanged
Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process
Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
Relief Reports Full-Year 2021 Results and Provides Corporate Update
Relief Reports Full-Year 2021 Results and Provides Corporate Update
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using Its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using Its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU
Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office
Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office
Evolva's Board of Directors intends to further strengthen its expertise at upcoming AGM and proposes, among others, the following agenda items:
Evolva's Board of Directors intends to further strengthen its expertise at upcoming AGM and proposes, among others, the following agenda items:
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
DGAP-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu, genehmigt die Dividende von CHF 3.85 pro Aktie und wählt zwei neue Verwaltungsräte
DGAP-News: Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu, genehmigt die Dividende von CHF 3.85 pro Aktie und wählt zwei neue Verwaltungsräte
DGAP-News: Shareholders at BB Biotech AG's AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members
DGAP-News: Shareholders at BB Biotech AG's AGM vote in favor of all proposals, approve the dividend of CHF 3.85 per share and elect two new board members
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
Kuros Biosciences reports results for the full year 2021
Kuros Biosciences reports results for the full year 2021
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
Evolva grew product-related revenue by 40% in 2021
Evolva grew product-related revenue by 40% in 2021
DGAP-News: BB Biotech AG publishes its 2021 annual report
DGAP-News: BB Biotech AG publishes its 2021 annual report
DGAP-News: BB Biotech AG veröffentlicht Geschäftsbericht 2021
DGAP-News: BB Biotech AG veröffentlicht Geschäftsbericht 2021
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
Evolva appoints Christian Wichert as new CEO to boost growth strategy and enter its next phase of development and commercialization
Evolva appoints Christian Wichert as new CEO to boost growth strategy and enter its next phase of development and commercialization
EQS-Adhoc: Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
EQS-Adhoc: Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
EQS-News: Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock